newsfilter
← Latest News
GlobeNewswire·

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

  • The U.S. FDA cleared Oculis Holding AG's Investigational New Drug (IND) application for Privosegtor to treat acute multiple sclerosis (MS) relapses.
  • Oculis will host an R&D Day on December 8, 2026, to provide updates on the Privosegtor development program for acute MS relapses & the ongoing PIONEER program in optic neuropathies.
  • The FDA confirmed Oculis can cross-reference data from the open Privosegtor ophthalmology-related IND & supported a strategy including patients with optic neuritis & other relapse types.
  • The proposed clinical development strategy utilizes a primary endpoint at three months & the same 3mg/kg daily dose for five days as used in the PIONEER-1 trial.
  • Privosegtor builds upon positive Phase 2 ACUITY trial results which demonstrated neuroprotective effects including improved visual function, preserved retinal ganglion cell integrity, & reduced biomarkers of axonal injury.
  • Privosegtor aims to become the first neuroprotective therapy to actively preserve nerve integrity during acute MS relapses, addressing an unmet need where current standard-of-care therapies only shorten attack duration.
  • Oculis plans to evaluate Privosegtor in a broad population of MS patients experiencing optic neuritis, ambulatory relapses, & other relapse types.
  • Dr. Riad Sherif, CEO of Oculis, stated the IND clearance marks a pivotal new era for the company in neurology & highlighted confidence based on the Phase 2 ACUITY data.
  • Dr. Amit Bar-Or, Professor of Neurology at the University of Pennsylvania, noted that a treatment protecting neurons during acute relapses would fill a gap in current care where recovery is often incomplete.
  • Privosegtor has received Breakthrough Therapy designation from the FDA & Priority Medicines (PRIME) designation from the EMA for optic neuritis.
  • Multiple sclerosis affects approximately 2.8 million people worldwide with an estimated 170,000 relapses occurring annually in the U.S. alone.
Company
Oculis Holding AG
Keywords
Nasdaq:OCS, Oculis Holding AG